Veterinary Medicines

Prednizol 5mg Tablets for Dogs and Cats

Authorised
  • Prednisolone
Download as PDF

Product identification

Medicine name:
Prednizol 5mg Tablets for Dogs and Cats
Prednizol 5 mg Tablet
Prednizol 5 mg Comprimé
Prednizol 5 mg Tablette
Active substance:
  • Prednisolone
Target species:
  • Dog
  • Cat
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Prednisolone
    5.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QH02AB06
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Package description:
  • Cardboard box of 1 PVC Aluminium/PVC foil blister of 10 tablets each
  • White polypropylene container containing 250 tablets, sealed with a white, childresistant, high-density polyethylene closure.
  • Cardboard box of 2 PVC Aluminium/PVC foil blisters of 10 tablets each
  • Cardboard box of 3 PVC Aluminium/PVC foil blisters of 10 tablets each
  • Cardboard box of 4 PVC Aluminium/PVC foil blisters of 10 tablets each
  • Cardboard box of 5 PVC Aluminium/PVC foil blisters of 10 tablets each
  • Cardboard box of 6 PVC Aluminium/PVC foil blisters of 10 tablets each
  • Cardboard box of 7 PVC Aluminium/PVC foil blisters of 10 tablets each
  • Cardboard box of 8 PVC Aluminium/PVC foil blisters of 10 tablets each
  • Cardboard box of 9 PVC Aluminium/PVC foil blisters of 10 tablets each
  • Cardboard box of 10 PVC Aluminium/PVC foil blisters of 10 tablets each
  • Cardboard box of 12 PVC Aluminium/PVC foil blisters of 10 tablets each
  • Cardboard box of 15 PVC Aluminium/PVC foil blisters of 10 tablets each
  • Cardboard box of 25 PVC Aluminium/PVC foil blisters of 10 tablets each
  • Cardboard box of 50 PVC Aluminium/PVC foil blisters of 10 tablets each

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Millpledge Europe
Marketing authorisation date:
Manufacturing sites for batch release:
  • Millpledge Europe
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
This information is not available for this product.
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0351/001
Concerned member states:
  • Belgium
  • France
  • Germany
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

English (PDF)
Published on: 1/11/2023
Updated on: 2/11/2023
Download

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 27/02/2024
Download
French (PDF)
Published on: 27/02/2024
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 27/02/2024
Download
French (PDF)
Published on: 27/02/2024
Download
German (PDF)
Published on: 27/02/2024
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 27/02/2024
Download
French (PDF)
Published on: 27/02/2024
Download
German (PDF)
Published on: 27/02/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."